Reversible facial nerve paralysis in a cat suspected to be associated with systemic hypertension

Laura Moretto¹, Robert Herzig², Katrin Beckmann², Nadja Wolfer³, Matthias Dennler³ and Tony M Glaus¹

Abstract
Case summary This report describes the appearance of facial nerve paralysis in a 16-year-old hypertensive cat. MRI was helpful in visualising and characterising mesencephalic and facial nerve lesions thought to be induced by hypertension. Neurological signs rapidly resolved under antihypertensive therapy.

Relevance and novel information Systemic hypertension is an important medical condition in geriatric cats causing damage in various target organs, including the brain. Hypertensive encephalopathy is an umbrella term for a multitude of different clinical manifestations of cerebral target organ damage. Facial nerve paralysis secondary to hypertension is recognised in human medicine, particularly in children, but so far has not been reported in veterinary medicine.

Keywords: Blood pressure; Doppler sphygmomanometry; hypertensive; encephalopathy; neurological; central nervous system

Accepted: 11 November 2021

Case summary A 16-year-old female spayed cat was referred to the division of neurology in order to investigate the cause of paralysis of the right eyelid associated with a corneal lesion. Hyperthyroidism had been diagnosed 2 months previously and the cat had been treated with transdermal thiamazole ointment since then. Four days before presentation to our hospital, blepharospasm of the right eye had been detected by the referring veterinarian and the cat was reported to be neurologically normal. The corneal lesion was detected by the referring veterinarian the day before presentation to our hospital.

On physical examination, the cat was lethargic and a palpable nodule of the thyroid was found, but the vital parameters were within normal limits. Neurological examination revealed right-sided loss of the palpebral reflex, loss of facial expression, drooping whiskers, and normal physiological, and no elicitable pathological, nystagmus. Posture, gait, muscle tone, spinal reflexes and evaluation of the remaining cranial nerves were unremarkable. The neurological deficits were neuroanatomically localised to the right facial nerve. Further diagnostic work-up included haematology and comprehensive biochemistry, a urinalysis, a fluorescein test, a Schirmer tear test, retinal examination, blood pressure (BP) measurement and MRI of the head. The only laboratory abnormality was a mild anaemia. The serum thyroid concentration (1.4 µg/dl) was within the

¹Division of Cardiology, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
²Division of Neurology, Clinic for Small Animal Surgery, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
³Clinic of Diagnostic Imaging, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland

Corresponding author: Tony M Glaus, Prof Dr med vet, Division of Cardiology, Clinic for Small Animal Internal Medicine, Winterthurerstrasse 260, Zurich 8057, Switzerland Email: tglaus@vetclinics.uzh.ch
The laboratory results are shown in Tables 1–3. BP measured by Doppler sphygmomanometry was severely elevated on a first set of measurements, with an average systolic value of 230 mmHg. To corroborate this finding a consecutive set of measurements was obtained 6 h later, and the systolic BP was still high at 215 mmHg. The Schirmer tear test was normal. A fundic examination did not reveal any retinal abnormalities. With a fluorescein test, a centrally located corneal lesion was confirmed, and a partial tarsorrhaphy was performed. Cerebral MRI (Ingenia 3T; Philips) was performed under general anaesthesia and revealed a small (height 3 mm × width 4 mm × length 4.3 mm), ovoid, ill-defined lesion in the mesencephalon (Figure 1). Compared with grey matter, the lesion appeared hypointense in T2-weighted (T2W) and fluid attenuated inversion recovery images, and isointense in T1-weighted (T1W). The lesion caused an area of signal void in T2W* (gradient echo) images and did not enhance after intravenous injection of gadolinium-based contrast medium (0.2 ml/kg [Dotarem; GE Healthcare]). The findings were consistent with an intra-axial early subacute haemorrhage in the mesencephalon. The right facial nerve was of normal thickness but enhanced more than the left facial nerve after contrast injection (Figure 2). Additional findings included a small space-occupying lesion originating from the pituitary gland, a thyroid nodule, mild fluid accumulation in the left tympanic cavity, mild mandibular and medial retropharyngeal lymphadenomegaly, mild thickening of the right nasal mucosa with mild fluid accumulation, and mild contrast enhancement of the conjunctivae of the right eye (Figure 3). Retinal abnormalities (ie, detachment) were not visible.

Based on all of the findings, the diagnoses were: right-sided facial nerve paralysis; corneal ulceration of the right eye; systemic hypertension probably associated with hyperthyroidism; well-controlled hyperthyroidism; cerebral, acute haemorrhagic infarct located in the mesencephalon; neuropathy of the facial nerve; suspicion of a pituitary adenoma; otitis media on the left side; non-destructive right-sided rhinitis; and regional lymphadenitis.

The cat received eye drops (Tobrex; tobramycin q8h for 10 days), was placed on antihypertensive medication (Amodip; amlodipine 1.25 mg PO q24h) and was maintained on transdermal thiamazole ointment (5 mg/0.1 ml at a dosage of 0.1 ml q12h applied to the ear pinnae). BP was rechecked after 5 days and was 140 mmHg. Three weeks after initial presentation the sutures from the partial tarsorrhaphy were removed. Facial nerve function was considered normal at this time. BP was measured

| Table 1 | Haematological results of a 16-year-old cat with hypertension and facial nerve paralysis |
| --- | --- | --- |
| Result RI | +7 months |
| Haematocrit (%) | 32 | 33.45 | 32 |
| Haemoglobin (g/l) | 11.2 | 11.3–15.5 | 11.4 |
| Erythrocytes (×10⁶/µl) | 8.3 | 7.0–10.7 | 8.2 |
| MCH (pg) | 13 | 14–17 | 14 |
| MCHC (g/dl) | 35 | 33–36 | 36 |
| MCV (fl) | 39 | 40–48 | 39 |
| Thrombocytes (×10⁹/µl) | 488 | 180–680 | 538 |
| Leukocytes | 12.7 | 4.6–12.8 | 21.7 |
| Segmented neutrophils | 9.6 | 2.3–10.0 | 18 |
| Eosinophils | 0.97 | 0.1–0.6 | 0.45 |
| Basophils | 0.01 | 0–0.14 | 0.03 |
| Monocytes | 0.55 | 0–0.7 | 0.6 |
| Lymphocytes | 1.57 | 1.1–6.0 | 2.6 |

RI = reference interval; MCH = mean cell haemoglobin; MCHC = mean cell haemoglobin concentration; MCV = mean cell volume

| Table 2 | Biochemical results of a 16-year-old cat with hypertension and facial nerve paralysis |
| --- | --- | --- |
| Result RI | +7 months |
| Bilirubin (µmol/l) | <2.5 | <3.5 | <2.5 |
| Glucose (mmol/l) | 5.6 | 4–9 | 6.8 |
| Urea (mmol/l) | 8.5 | 7.4–12.6 | 6.5 |
| Creatinine (µmol/l) | 95 | 98–163 | 95 |
| Protein (g/l) | 77 | 64–80 | 75 |
| Albumin (g/l) | 35 | 32–42 | 31 |
| Cholesterol (mmol/l) | 3.2 | 2.6–6.8 | 3 |
| ALP (IU/l) | 23 | 16–43 | 20 |
| ALT (IU/l) | 29 | 34–98 | 29 |
| Lipase (mmol/l) | 8 | 6–21 | 8 |
| Natrium (mmol/l) | 157 | 150–157 | 151 |
| Kalium (mmol/l) | 4.5 | 3.8–5.4 | 3.8 |
| Chloride (mmol/l) | 124 | 113–123 | 116 |
| Calcium (mmol/l) | 2.39 | 2.40–2.80 | 2.37 |
| Phosphate (mmol/l) | 1.13 | 0.9–1.8 | 0.9 |
| T4 (µg/dl) | 1.4 | <3.3 | 2.5 |

RI = reference interval; ALP = alkaline phosphatase; ALT = alanine transaminase; T4 = thyroxine

| Table 3 | Urinalysis of a 16-year-old cat with hypertension and facial nerve paralysis |
| --- | --- |
| Result |
| Colour | Light yellow |
| Specific gravity | 1029 |
| pH | 6 |
| Protein | + |
| Glucose | – |
| Ketone | – |
| Bilirubin | – |
| Blood/haemoglobin | – |
| Sediment | Inactive |

reference interval. The laboratory results are shown in Tables 1–3. BP measured by Doppler sphygmomanometry was severely elevated on a first set of measurements, with an average systolic value of 230 mmHg. To corroborate this finding a consecutive set of measurements was obtained 6 h later, and the systolic BP was still high at 215 mmHg. The Schirmer tear test was normal. A fundic examination did not reveal any retinal abnormalities. With a fluorescein test, a centrally located corneal lesion was confirmed, and a partial tarsorrhaphy was performed. Cerebral MRI (Ingenia 3T; Philips) was performed under general anaesthesia and revealed a small (height 3 mm × width 4 mm × length 4.3 mm), ovoid, ill-defined lesion in the mesencephalon (Figure 1). Compared with grey matter, the lesion appeared hypointense in T2-weighted (T2W) and fluid attenuated inversion recovery images, and isointense in T1-weighted (T1W). The lesion caused an area of signal void in T2W* (gradient echo) images and did not enhance after intravenous injection of gadolinium-based contrast medium (0.2 ml/kg [Dotarem; GE Healthcare]). The findings were consistent with an intra-axial early subacute haemorrhage in the mesencephalon. The right facial nerve was of normal thickness but enhanced more than the left facial nerve after contrast injection (Figure 2). Additional findings included a small space-occupying lesion originating from the pituitary gland, a thyroid nodule, mild fluid accumulation in the left tympanic cavity, mild mandibular and medial retropharyngeal lymphadenomegaly, mild thickening of the right nasal mucosa with mild fluid accumulation, and mild contrast enhancement of the conjunctivae of the right eye (Figure 3). Retinal abnormalities (ie, detachment) were not visible.

Based on all of the findings, the diagnoses were: right-sided facial nerve paralysis; corneal ulceration of the right eye; systemic hypertension probably associated with hyperthyroidism; well-controlled hyperthyroidism; cerebral, acute haemorrhagic infarct located in the mesencephalon; neuropathy of the facial nerve; suspicion of a pituitary adenoma; otitis media on the left side; non-destructive right-sided rhinitis; and regional lymphadenitis.

The cat received eye drops (Tobrex; tobramycin q8h for 10 days), was placed on antihypertensive medication (Amodip; amlodipine 1.25 mg PO q24h) and was maintained on transdermal thiamazole ointment (5 mg/0.1 ml at a dosage of 0.1 ml q12h applied to the ear pinnae). BP was rechecked after 5 days and was 140 mmHg. Three weeks after initial presentation the sutures from the partial tarsorrhaphy were removed. Facial nerve function was considered normal at this time. BP was measured
at 170 mmHg; amlodipine was kept unchanged (1.25 mg, q24h, in the morning), but telmisartan was added (1 mg/kg, q24h, in the evening). Two months after initial presentation, the cat remained neurologically normal, serum thyroxine was normal (1.6 µg/dl) and BP was 150 mmHg. The cat was episodically rechecked. At the time of writing, 20 months after initial presentation, based on a telephone call with the owner, the cat remained clinically neurologically normal.

**Discussion**

In human medicine, non-congenital facial nerve paralysis is uncommon and mostly diagnosed as idiopathic (Bell’s palsy). In addition, facial nerve paralysis has been reported as the initial feature of systemic hypertension, mainly in children, but also in adults. In children, hypertension leading to facial nerve paralysis is mostly caused by renal disease. The pathology behind this is believed to be haemorrhage into the facial nerve canal and/or vascular insults, which results in pressure on the facial nerve causing paralysis. The facial nerve is thought to be particularly vulnerable to haemorrhagic or oedematous injury due to the enclosed space of the fallopian canal.

In cats, reports on facial nerve paralysis are scant and otitis media is considered the most common cause. Other identified causes of isolated facial nerve dysfunction have included surgical and non-surgical trauma and neoplasia; in 25% of the cats in one study, facial nerve paralysis was judged to be idiopathic. Finally, facial nerve dysfunction has been described to be associated

**Figure 1** Cerebral MRI examination images of a 16-year-old cat with acute unilateral facial nerve paralysis. (a) Transverse T2-weighted (T2W); (b) transverse T1-weighted (T1W); (c) dorsal T2W; (d) transverse T2W* (gradient echo); (e) transverse T1W (gradient echo), after intravenous injection of contrast medium; and (f) sagittal T2 images. A small, ill-defined lesion (white arrows) was identified in the mesencephalon. Compared with grey matter, the lesion was hypointense in T2W and isointense in T1W images. It caused signal void in T2W* images and did not enhance after contrast injection. The findings were consistent with acute haemorrhage. R = right; L = left

**Figure 2** Transverse T1-weighted (gradient echo) image after intravenous injection of contrast medium. The right (R) facial nerve (solid arrow) had the same diameter as the left facial nerve (dashed arrow) but showed enhancement after contrast administration compared with the unenhanced left (L) side
with a generalised polyneuropathy. Ultimately, the idiopathic disorder is a diagnosis of exclusion that is based on the inability to diagnose any causative abnormality using routine MRI or CT, evaluation of cerebrospinal fluid and metabolic studies; the availability of high-quality MRI is fairly recent, however.

Reported MRI changes in hypertensive facial nerve paralysis in children are limited and include pontine haemorrhage at the site of the facial nucleus, ischaemic stroke in the pons affecting the post-nuclear facial fibres, multiple ischaemic infarcts in the periventricular white matter and an oedematous nerve sheath with vessel engorgement. In adults, diffuse enhancement of the facial nerve from the fallopian canal to the stylomastoid foramen had been considered diagnostic for Bell’s palsy (ie, idiopathic facial nerve paralysis); however, Bell’s palsy in humans is no longer not only considered idiopathic, but also caused by hypertension.

In the reported cat, the MRI revealed several abnormalities: (1) changes in the mesencephalon, but not in the area of the facial nerve nucleus, consistent with hypertension-induced haemorrhage; (2) ipsilateral contrast enhancement of the facial nerve, indicating a disrupted blood–nerve barrier, allowing leakage and
accumulation of contrast material; and (3) changes in the contralateral bulla tympanica together with signs of rhinitis. The last might imply that there was also ipsilateral otitis media, it was just not visible on MRI. Thus, the unilateral facial nerve paralysis in this cat could have been a result of otitis media, hypertension or neuritis, or it could have been idiopathic. Whereas resolution of the paralysis within 3 weeks of the commencement of antihypertensive treatment may suggest that hypertension played a central pathophysiological role, spontaneous resolution of the facial nerve paralysis was also possible.

In people, various case series have reported the incidence of facial palsy to be 4–17% in children with malignant hypertension. Apparently not uncommonly, a wrong diagnosis of idiopathic facial nerve paralysis is made because malignant hypertension is overlooked. In one retrospective review, the time between first facial nerve deficits and the diagnosis of severe systemic hypertension was a median of 45 days (range 0 days to 2 years). Thus, it is recommended that BP is measured in all patients with facial nerve paralysis. The majority of patients with hypertension-induced facial nerve paralysis showed gradual resolution of the paralysis when BP was well controlled, and reoccurrence of signs corresponded with an exacerbation of the hypertension. Systemic hypertension was thought to be caused by hyperthyroidism in the cat in this report, as hyperthyroidism is reportedly the second most common cause of hypertension in cats. The most common cause of hypertension in cats is chronic kidney disease, but the urine specific gravity at admission and the repeatedly (low) normal kidney values were not suggestive of this. Other causes of hypertension in cats are rare. In the view of repeatedly normal serum potassium, no additional diagnostic tests, such as abdominal ultrasound and serum aldosterone measurements, were performed to rule in hyperaldosteronism. However, normal potassium does not rule out hyperaldosteronism (in people). Additional rare causes are hypersomatotropism and phaeochromocytoma. The MRI finding of a pituitary mass could support hypersomatotropism. However, hypersomatotropism that does not eventually cause diabetes mellitus would be unusual. Other functional pituitary tumours, such as those leading to pituitary-dependent hyperadrenocorticism, are possible; again, chronic hyperadrenocorticism in a cat without diabetes mellitus or dermatological abnormalities would be very unusual, however. In the cat in this report, no further endocrinological tests were performed to rule in hyperaldosteronism, hypersomatotropism, hyperadrenocorticism or phaeochromocytoma. Finally, the cause of hypertension might have been idiopathic; however, idiopathic hypertension is usually a diagnosis of exclusion, and as hyperthyroidism is a recognised cause, this was the suspected cause in this cat.

Conclusions
Systemic hypertension may induce isolated facial nerve paralysis in cats. Considering similar reports in human medicine, it may be speculated that hypertension as a cause of so-called idiopathic facial nerve paralysis has also been underdiagnosed in cats because BP may not have been routinely measured in affected cases.

Conflict of interest
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

Ethical approval
The work described in this manuscript involved the use of non-experimental (owned or unowned) animals. Established internationally recognised high standards ('best practice') of veterinary clinical care for the individual patient were always followed. Ethical approval from a committee was therefore not specifically required for publication in JEMS Open Reports. Although not required, where ethical approval was still obtained it is stated in the manuscript.

Informed consent
Informed consent (verbal or written) was obtained from the owner or legal custodian of all animal(s) described in this work (experimental or non-experimental animals, including cadavers) for all procedure(s) undertaken (prospective or retrospective studies). No animals or people are identifiable within this publication, and therefore additional informed consent for publication was not required.

ORCID iDs
Robert Herzig https://orcid.org/0000-0002-9216-8462
Katrin Beckmann https://orcid.org/0000-0002-1823-7845
Tony M Glaus https://orcid.org/0000-0003-2456-9536

References
1. Petersen E. Bell’s palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol Suppl 2002; 549: 4–30.
2. Rowlands S, Hooper R, Hughes R, et al. The epidemiology and treatment of Bell’s palsy in the UK. Eur J Neurol 2002; 9: 63–67.
3. Morris AM, Deeks SL, Hill MD, et al. Annualized incidence and spectrum of illness from an outbreak investigation of Bell’s palsy. Neuroepidemiology 2002; 21: 255–261.
4. Lorch M and Teach SJ. Facial nerve palsy – etiology and approach to diagnosis and treatment. Pediatr Emer Care 2010; 26: 763–772.
5. Lloyd AV, Jewitt DE and Still JD. Facial paralysis in children with hypertension. Arch Dis Child 1966; 41: 292–294.
6. Jörg R, Milani GP, Simonetti GD, et al. Peripheral facial nerve palsy in severe systemic hypertension: a systematic review. Am J Hypertens 2013; 26: 351–356.
7 Trompeter RS, Smith RL, Hoare RD, et al. Neurological complications of arterial hypertension. Arch Dis Child 1982; 57: 913–917.
8 Still JL and Cottom D. Severe hypertension in childhood. Arch Dis Child 1967; 42: 34–39.
9 Ellis SL, Carter BL, Leehey MA, et al. Bell’s palsy in an older patient with uncontrolled hypertension due to medication nonadherence. Ann Pharmacother 1999; 33: 1269–1273.
10 de Lahunta A, Glass E and Kent M. Lower motor neuron: general somatic efferent, cranial nerve. Cranial nerve VII: facial neurons. In: de Lahunta A, Glass E and Kent M (eds). Veterinary neuroanatomy and clinical neurology. 4th ed. St Louis, MO: Elsevier Saunders, 2015, pp 172–180.
11 Kern TJ and Erb HN. Facial neuropathy in dogs and cats: 95 cases (1975–1985). J Am Vet Med Assoc 1987; 191: 1604–1609.
12 Holland CT. Asymmetrical focal neurological deficits in dogs and cats with naturally occurring tick paralysis (Ixodes holocyclus): 27 cases (1999–2006). Aust Vet J 2008; 86: 377–384.
13 Tien R, Dillon WP and Jackler RK. Contrast-enhanced MR imaging of the facial nerve in 11 patients with Bell’s palsy. Am J Roentgenol 1990; 155: 573–579.
14 Saremi F, Helmy M, Farzin S, et al. MRI of cranial nerve enhancement. Am J Roentgenol 2005; 185: 1487–1497.
15 Tomek M, Nandoskar A, Chapman N, et al. Facial nerve palsy in the setting of malignant hypertension: a link not to be missed. Q J Med 2015; 108: 145–146.
16 Huhtinen M, Derré G, Renoldi HJ, et al. Randomized placebo-controlled clinical trial of a chewable formulation of amlodipine for the treatment of hypertension in client-owned cats. J Vet Intern Med 2015; 29: 786–793.
17 Glaus TM, Elliott J, Herberich E, et al. Efficacy of long-term oral telmisartan treatment in cats with hypertension: results of a prospective European clinical trial. J Vet Intern Med 2019; 33: 413–422.
18 Schirpenbach C, Segmiller F, Diederich S, et al. The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry. Dtsch Arztebl Int 2009; 106: 305–311.
19 Myers JA, Lunn KF and Bright JM. Echocardiographic findings in 11 cats with acromegaly. J Vet Intern Med 2014; 28: 1235–1238.
20 Daniel G, Mahony OM, Markovich JE, et al. Clinical findings, diagnostics and outcome in 33 cats with adrenal neoplasia (2002–2013). J Feline Med Surg 2016; 18: 77–84.
21 Cook AK and Evans JB. Feline comorbidities: recognition, diagnosis and management of the cushingoid diabetic. J Feline Med Surg 2021; 23: 4–16.